Pacific Biosciences of California, Inc. (PACB) Company Bio
Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.
PACB Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Pacific Biosciences Of California Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Pacific Biosciences Of California Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Pacific Biosciences Of California Inc ended up being:
As a business, PACB is generating more cash flow than only 18.61% of positive cash flow stocks in the Healthcare.
The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 5.92% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Pacific Biosciences Of California Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -47.28. This coverage rate is greater than that of only 2.71% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Pacific Biosciences Of California Inc? See AGHC, ALC, AMRN, ATRS, and MOR.
(Jan 2021 trend research report ) Latest research report on Market 2020 DNA Sequencing published by insightSLICE, starts with the market description, executive report, segmentation and classification. The report offers a comprehensive analysis of the market so that readers can
DUBLIN--(BUSINESS WIRE)--The "Next Generation Sequencing Global Market Opportunities and Strategies 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering. Next Generation Sequencing Global Market Opportunities and Strategies 2020-30: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global next generation sequencing market. The global next generation sequencing
"This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. . In the daily Japanese candlestick chart of PACB, below, we can see that the shares corrected modestly after our Dec. 9 review and subsequently rallied to the $39 price target. This chart shows that prices are above the rising 50-day moving average line and trade at more than three times the level of the rising 200-day moving average line.